|
|
Article: Review Shows Extended-Release amoxicillin/clavulanate Formulation, Augmentin XR(TM), Highly Effective for Acute Bacterial Rhinosinusitis (ABRS).
- Article from:
- PR Newswire
- Article date:
- August 19, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Treatment Evolves to Combat Antibiotic Resistance
- A specially engineered formulation of amoxicillin/clavulanate, GlaxoSmithKline's Augmentin XR(TM) (amoxicillin/clavulanate potassium) Extended Release Tablets, is effective in treating acute bacterial rhinosinusitis (ABRS), according to a review published in the June issue of Clinics in Laboratory Medicine (vol. 24, pages 531-551). This is despite significant prevalence of resistance to commonly used antimicrobials in bacteria that cause ABRS. The evolution of amoxicillin/clavulanate in the treatment of adults with ABRS and community- acquired pneumonia (CAP) in response to antimicrobial resistance patterns was ...